Toby A Ferguson
Overview
Explore the profile of Toby A Ferguson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
937
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lovett A, Chary S, Babu S, Bruneteau G, Glass J, Karlsborg M, et al.
Muscle Nerve
. 2025 Feb;
PMID: 40017137
Introduction/aims: Tofersen is approved for the treatment of amyotrophic lateral sclerosis (ALS) due to superoxide dismutase 1 mutations (SOD1-ALS). Here we report serious neurologic adverse events (AEs) that occurred in...
2.
van den Berg L, Rothstein J, Shaw P, Babu S, Benatar M, Bucelli R, et al.
Lancet Neurol
. 2024 Jul;
23(9):901-912.
PMID: 39059407
Background: Hexanucleotide repeat expansion of C9orf72 is a common genetic cause of amyotrophic lateral sclerosis (ALS). No C9orf72-targeted treatments are available. BIIB078 is an investigational antisense oligonucleotide targeting C9orf72 sense...
3.
Ferguson T, Vozenilek J, West C
Dev Growth Differ
. 2023 Jun;
36(6):597-604.
PMID: 37282136
As a result of transfecting Dictyostelium discoideum with an actin 6/lacZ fusion transgene, strain HW80 was created which expresses the β-galactosidase gene product uniformly throughout development. When mixed with an...
4.
Miller T, Cudkowicz M, Genge A, Shaw P, Sobue G, Bucelli R, et al.
N Engl J Med
. 2022 Sep;
387(12):1099-1110.
PMID: 36129998
Background: The intrathecally administered antisense oligonucleotide tofersen reduces synthesis of the superoxide dismutase 1 (SOD1) protein and is being studied in patients with amyotrophic lateral sclerosis (ALS) associated with mutations...
5.
Vucic S, Ferguson T, Cummings C, Hotchkin M, Genge A, Glanzman R, et al.
Muscle Nerve
. 2021 Aug;
64(5):532-537.
PMID: 34378224
Diagnostic criteria for amyotrophic lateral sclerosis (ALS) are complex, incorporating multiple levels of certainty from possible through to definite, and are thereby prone to error. Specifically, interrater variability was previously...
6.
Shin Y, Liu D, Sang H, Ferguson T, Song P
Stat Med
. 2021 Mar;
40(13):3035-3052.
PMID: 33763884
Amyotrophic lateral sclerosis (ALS) is a neurological disease that starts at a focal point and gradually spreads to other parts of the nervous system. One of the main clinical symptoms...
7.
Miller T, Cudkowicz M, Shaw P, Andersen P, Atassi N, Bucelli R, et al.
N Engl J Med
. 2020 Jul;
383(2):109-119.
PMID: 32640130
Background: Tofersen is an antisense oligonucleotide that mediates the degradation of superoxide dismutase 1 (SOD1) messenger RNA to reduce SOD1 protein synthesis. Intrathecal administration of tofersen is being studied for...
8.
van Eijk R, Nikolakopoulos S, Roes K, Middelkoop B, Ferguson T, Shaw P, et al.
J Neurol Neurosurg Psychiatry
. 2019 Jul;
90(12):1331-1337.
PMID: 31292200
Background: Funding and resources for low prevalent neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) are limited, and optimising their use is vital for efficient drug development. In this study,...
9.
Shin Y, Sang H, Liu D, Ferguson T, Song P
Biometrics
. 2019 Jun;
75(4):1310-1320.
PMID: 31254387
This paper focuses on analysis of spatiotemporal binary data with absorbing states. The research was motivated by a clinical study on amyotrophic lateral sclerosis (ALS), a neurological disease marked by...
10.
Kovalchuk M, Heuberger J, Sleutjes B, Ziagkos D, van den Berg L, Ferguson T, et al.
Clin Pharmacol Ther
. 2018 Apr;
104(6):1136-1145.
PMID: 29672831
Increased excitability of motor neurons in patients with amyotrophic lateral sclerosis (ALS) may be a relevant factor leading to motor neuron damage. This randomized, double-blind, three-way crossover, placebo-controlled study evaluated...